GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Other Long-Term Liabilities

InnoCare Pharma (FRA:33C) Other Long-Term Liabilities : €73.78 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Other Long-Term Liabilities?

InnoCare Pharma's other long-term liabilities for the quarter that ended in Dec. 2023 was €73.78 Mil.

InnoCare Pharma's quarterly other long-term liabilities increased from Jun. 2023 (€73.74 Mil) to Sep. 2023 (€75.51 Mil) but then declined from Sep. 2023 (€75.51 Mil) to Dec. 2023 (€73.78 Mil).

InnoCare Pharma's annual other long-term liabilities increased from Dec. 2021 (€22.41 Mil) to Dec. 2022 (€76.63 Mil) but then declined from Dec. 2022 (€76.63 Mil) to Dec. 2023 (€73.78 Mil).

InnoCare Pharma Other Long-Term Liabilities Historical Data

The historical data trend for InnoCare Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Other Long-Term Liabilities Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial - - - - -

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InnoCare Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

InnoCare Pharma Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Other Long-Term Liabilities
Comparable Companies
HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02162 HKSE:06826 HKSE:02315 HKSE:01530 HKSE:06955 HKSE:02105 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
09969:Hong Kong 33C:Germany 688428:China
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
Website
https://www.innocarepharma.com
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines